Respiratory Syncytial Virus

By Kenneth Navarro, Assistant Professor, Emergency Medicine Education University of Texas Southwestern Medical Center at Dallas
You and your partner continue highflow oxygen therapy while placing the child in an upright position to facilitate ventilation. You place the patient on an ECG monitor, which reveals a sinus tachycardia without ectopy. You also place the patient on a capnograph, which reveals a end-tidal carbon dioxide reading of 55 mm Hg.
On arrival at the emergency department (ED), the child has a slightly depressed level of consciousness with occasional tonic movements. Blood gas analysis confirms a moderate respiratory acidosis. The ED staff sedates the infant, intubates the child's trachea, and places the child on a mechanical ventilator. Immediately after intubation, the tube fills will a thin, frothy pink secretion that is easily suctioned. The ED physician begins intravenous steroid and antibiotic therapy and transfers the child to an isolation room in the pediatric intensive care unit. Serological tests confirm the presence of respiratory syncytial virus and sputum secretions do
Introduction
Respiratory syncytial virus (RSV) is a potentially life-threatening infection commonly associated with pediatric patients. However, the virus also represents a significant threat to adults, especially those with pre-existing respiratory problems. This module will explore the pathophysiology, assessment and management of RSV infections.
After isolating the respiratory syncytial virus for the first time, researchers attributed RSV to epidemic bronchiolitis in infants (Chanock, Roizman, & Myers, 1957) . RSV is the leading cause of viral bronchiolitis and pneumonia in the pediatric population (Nokes & Cane, 2008) , and many clinicians continue to consider RSV to be primarily a pediatric pathogen (Henderson, 1987) . Over two-thirds of all newborns will become infected with RSV within the first year of their life (Glezen, Taber, Frank, & Kasel, 1986) . Mortality rates for infants are 10 times higher for RSV infections than influenza infections, resulting in the death of about 3 percent of all infants hospitalized with RSV (Thompson et al., 2003) . Most children who die were previously healthy, although certain medical conditions increase the chances of death, including prematurity, chronic lung disease, congenital heart disease or immunodeficiency (Boyce, Mellen, Mitchel, Wright, & Griffin, 2000; Wang, Law, & Stephens, 1995) . RSV outbreaks have resulted in significant morbidity and mortality among patients hospitalized in neonatal intensive care units (Abadesso, Almeida, Virella, Carreiro, Machado, 2004; Cox, Rao, & Brandon-Cox, 2001; Dizdar et al., 2010; Kilani, 2002; Kurz, Herbich, Janata, Sterniste, & Bauer, 2008; Thorburn, Kerr, Taylor, & van Saene, 2004 ).
More recently, RSV is emerging as a significant source of respiratory illness among certain adult groups (Dowell et al., 1996; Falsey, Hennessey, Formica, Cox, & Walsh, 2005; Fleming & Cross, 1993; La Montagne, 1997; Sikkel, Quint, Mallia, Wedzicha, & Johnston, 2008; Thompson et al., 2003) . Reports of RSV outbreaks among nursing home patients appeared in the 1970s, resulting in associated pneumonia with mortality rates as high as 55 percent (Agius et al., 1990; Garvie & Gray, 1980; Hart, 1984; Mandal, Joglekar, & Khan, 1985; Public Health Laboratory Service Communicable Diseases Surveillance Centre, 1983; Sorvillo et al., 1984) . Researchers have established an association between chronic cardiopulmonary disease, an immunocompromised state and advanced age with increased complications in adult patients who contract RSV (Griffin et al., 2002; Englund et al., 1988) . RSV may also play a role in chronic obstructive pulmonary disease (COPD) exacerbation, a hypothesis that is supported indirectly by seasonal increases in COPD frequency that mirror the seasonal frequency of RSV hospitalization in children (McManus, Coyle, & Kidney, 2006) . Experts estimate that over 10,000 Americans over the age of 65 die each year from complications directly association with RSV infection (Thompson et al., 2003) .
Most RSV infections occur between November and May (Brandenburg, Neijens, & Osterhaus, 2001 ) with January and February being the peak months (Centers for Disease Control and Prevention, 2007) .
Virology, pathophysiology and transmission
Viruses are small pieces of genetic material surrounded by a protective protein capsule and, in some cases, a secondary capsule made of lipids, otherwise known as fats. RSV belongs to the same family of viruses that cause measles, mumps and parainfluenza. Genetic variations of RSV produce various strains, which may produce subtle differences in disease severity Martinello, Chen, Weibel, & Kahn, 2002; McConnochie, Hall, Walsh, & Roghmann, 1990; Mufson, Akerlind-Stopner, Orvell, Belshe, & Norrby, 1991; Walsh, McConnochie, Long, & Hall, 1997) by activating alternative chemical responses in the human body or through variations in viral replication methods (DeVincenzo, 2004) .
RSV infection of the lining of the patient's respiratory tract produces changes that promote respiratory distress (Atreya & Kulkarni, 1999; Ferris, Aherne, Locke, McQuillin, & Gardner, 1973) . After entering the ciliated host cells, RSV causes the cells to swell and protrude into the airway lumen, thereby narrowing the passageway for airflow. The cilia become ineffective at clearing away mucus (Mohapatra & Boyapalle, 2008) . RSV also causes the infected cell to fuse with adjacent cells creating a large mass of protoplasm containing many nuclei. This multi-nucleated mass is called a syncytium (sin sish' e əm).
Swelling and merging of the respiratory tract lining subsequently fills the airway lumen with mucus and cellular debris. In an attempt to fight the viral invasion, white blood cells rush into the tissue surrounding the airway, resulting in peri-bronchiolar swelling. These conditions combine to completely obstruct the smaller bronchioles during exhalation. Inhalation allows sufficient dilation of the bronchioles to permit air entry however, obstruction during exhalation results in air trapping and hyperinflation of the patient's alveoli. The patient begins accumulating carbon dioxide resulting in respiratory acidosis and hypoxemia.
Although transmission of the virus to your body increases the chances of you becoming ill, exposure and transmission does not necessarily mean that you will get sick. There are a variety of factors that determine whether exposure to the virus results in illness.
RSV is transmitted from person to person through close contact, droplets, or fomites (Mohapatra & Boyapalle, 2008) . In direct transmission, the person carrying the virus directly contaminates a susceptible host through physical contact. If an infected patient touches your bare skin for example, the virus could transfer from the patient to you. Inadequate disinfection of your skin following direct contact could allow the virus to colonize your body.
Indirect transmission occurs when people touch fomites, the formal name for contaminated non-living objects. Fomites can be gloves, paper tissues, doorknobs, water faucets or any surface in the back of the ambulance. Many types of infectious organisms can survive for extended periods on stretchers, oxygen regulators, stethoscopes or ECG cables. RSV in secretions can survive for hours on countertops, gloves and tissue and can remain infectious for about half an hour on skin surfaces (Wong, 1995) .
When patients colonized with infectious viruses cough or sneeze into the open, tiny water droplets containing the virus can float in the air. If someone else inhales those droplets, the virus moves from one person to another via the airborne route. Droplets not inhaled can settle onto surfaces with dust particles, which can become airborne again when disturbed.
A virus that lands on your skin or mucus membranes results in contamination. It does not necessarily mean that the virus will stay around long enough to cause any problems. The virus must survive your body's natural defense mechanisms. For example, viruses that land on the surface of your skin must withstand the harsh environmental conditions present. Viruses that land on your respiratory membranes must overcome the action of mucus and cilia, which protect airway structures. If the virus can survive, contamination becomes colonization as the virus begins reproducing (Creager, Black, & Davison, 1990) .
Under normal circumstances, you do not get sick following contamination or colonization regardless of the exposure route. The human body has many additional protective mechanisms that keep viruses from causing disease. However, if the virus can get past your defenses, you could develop a infection. Even if the infection never develops, you can spread the virus to other patients.
RSV infection begins when a virus binds to the host cell (Falsey, 2007) . Binding requires proteins on the RSV surface membrane to interact with proteins on the host cell membrane (Miyairi & DeVincenzo, 2008) . Once binding occurs, the virus injects the host cell with a small piece of genetic material that hijacks the protein manufacturing machinery of that cell. Once this happens, the host cell stops performing its normal functions and begins creating new viruses. Because this viral replication occurs within normal cells, your protective white blood cells cannot get to the virus to stop them.
Young adults can shed the respiratory syncytial virus and remain infectious for three to six days (Hall, Hall, Speers, 1978) ; infants can be infectious up to three times longer (Hall, Douglas, & Geiman, 1976) .
The fact that RSV infections can occur throughout an individual's lifespan indicates that infection and recovery does not provide complete immunity (Falsey, 2007) . However, animal and human studies suggest that prior infection induces antibody response that can provide at least partial immunity and mitigate future disease severity (Lamprecht, Krause, & Mufson, 1976; Walsh, Hall, Briselli, Brandriss, & Schlesinger, 1987; Walsh, Schlesinger, & Brandriss, 1984) . To date, researchers have failed to produce an approved vaccine against RSV (Nokes & Cane, 2008) , however, researchers have identified several candidates for an effective RSV vaccine (Falsey & Walsh, 1996; Teng et al., 2000; Wright et al., 2000) .
Assessment
It is often difficult to distinguish RSV infection from influenza or other upper respiratory tract infections. The presence of bronchiolitis in infants suggests the presence of RSV (Falsey, 2007) . No strong predictor exists for adult patients, as most present with nasal congestion and cough, which overlap any number of wintertime viruses. Definitive diagnosis of RSV infection requires laboratory testing.
RSV infection appears as a mild to moderately severe upper respiratory illness (Johnson, Bloom, Mufson, & Chanock, 1962) . In the initial stages, most patients have a runny nose, cough or sneeze and suffer from a sore throat. About one-fourth of young adults will develop lower respiratory tract symptoms and about half will experience fever (Hall, Long, & Schnabel, 2001) . Wheezing is also a common symptom in infants and young children.
As the infection progresses, the wheezing and coughing becomes more pronounced. The patient may have an increased work of breathing that includes the use of accessory respiratory muscles. With increased air hunger and hypoxemia comes cyanosis.
Late in the disease progression, the patient will experience a decreased level of consciousness. Although the patient may exhibit profound tachypnea, there will be poor air exchange resulting in decreased or absent breath sounds. The patient may periodically experience apneic spells.
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Treatment
Most patients with RSV infection require symptom treatment only. You should ensure adequate oxygenation and minimize any unpleasant symptoms the patient experiences. Allow the patient to assume any position that provides optimal ventilatory effort.
Administer enough oxygen to keep the patient from becoming hypoxemic. In all but the most severe cases, nasal cannula oxygen administration will result in immediate improvement of pulse oximetry readings and begin to alleviate some of the distress. Certainly if there is no improvement, use higher flow rates.
Patients infected with RSV rarely need large volumes of intravenous (IV) fluid. If the patient is responding well to noninvasive therapy, there is no need to stick them with a needle. However, consider the potential of IV drug administration and if needed, secure venous access. An acceptable alternative to the traditional IV is the use of a saline lock. Infants and young children may become dehydrated more rapidly than adults because of increased respiratory rates and decreased oral intake. They may be unable to access fluids themselves and may require supplemental IV fluids, but only if depleted.
Patients who are wheezing may benefit from the prehospital administration of inhaled bronchodilators. This class of medication acts on the beta-receptors in the body. There are two types of betareceptors, designated as beta-one and beta-two. Stimulation of beta-one receptors will produce tachycardia, nausea, and will make the patient jittery. These side effects are not particularly beneficial in treating dyspnea. Beta-two receptor stimulation causes bronchodilation, among other things. This bronchodilation will protect the patient against any bronchoconstrictive stimuli. In addition, they enhance mucociliary clearance.
Two common beta-agonists used in the prehospital setting are albuterol and epinephrine. Epinephrine has strong beta-one and strong beta-two properties. Albuterol has strong beta-two properties and much weaker beta-one properties.
Beta-two agonists administered by inhalation via metered-dose inhaler (MDI) or small-volume nebulizer (SVN) to both adults and children have several advantages. These routes act in less than five minutes and have the fewest beta-one side effects. The optimal dose is titratable and patient-specific.
Begin with albuterol 2.5 mg in 3 ml normal saline via small volume nebulizer with oxygen set at 6 liters/min. You may use the same dose for the pediatric patient that you do for the adult patient. Do not be discouraged if the patient does not immediately improve following the first dose. Repetitive administration of albuterol produces incremental bronchodilation. Some patients will demonstrate clinical improvement after the first or second dose; some will require several more. Since albuterol stimulates the sympathetic nervous system, higher doses can result in rapid or irregular heart rate, shakiness or nervousness, and/or nausea.
The other beta-two agonist, epinephrine, relaxes bronchial smooth muscles although its effects on alphareceptors causes constriction of the bronchial arterioles. Epinephrine reduces congestion and edema and, thus, improves pulmonary function. It has an onset of detectable systemic levels within five to ten minutes after subcutaneous injection and reaches peak blood levels between twenty and forty minutes later. Its bronchodilating effects last up to four hours. A 0.3 -0.5 milligram subcutaneous injection of epinephrine 1:1,000 given to a conscious patient who is not exhausted and has adequate baseline cardiopulmonary reserves may provide immediate bronchodilation and eliminate the need for intubation. Unfortunately, epinephrine increases myocardial irritability and may precipitate cardiac dysrhythmia.
Although case reports and studies involving very small patient samples demonstrate reduction in work of breathing and improvement in gas exchange with continuous positive airway pressure (CPAP) therapy for bronchiolitis (Beasley & Jones, 1981; Cambonie et al., 2008; McNamara & Sullivan, 1997) , there are no trials that definitively show the utility of CPAP for these patients. Although, CPAP may prevent collapse and complete obstruction in smaller airways, the therapy may contribute to alveolar overinflation (Greenough, 2009 ).
Infection control
Clustering of RSV infections within specific areas of the hospital suggest that health care personnel are quite capable of acting as a vector for person to person transmission (Falsey, Treanor, Betts, & Walsh, 1992) . Since health care workers are capable of transmitting the virus from infected to non-infected patients, you play an important role in stopping the spread of RSV. Most experts agree that proper hand washing is the single most effective way of preventing the spread of infection (Fridkin & Raynes, 1999) . Unfortunately, health care providers across multiple disciplines do not wash their hands as often or as effectively as they should (Karabey, Ay, Derbentli, Nakipoglu, & Esen, 2002; Pittet, Mourouga, Perneger, 1999) . Medical personnel could significantly reduce the rate of pathogen colonization by increasing hand hygiene compliance (Sebille, Cheveret, & Valleron, 1997; Pittet et al., 2000) .
In the field, where soap and water are not immediately available, you should use commercial waterless hand cleaners. Upon arrival at the hospital, wash your hands as soon as possible after transferring patient care to the emergency department staff.
Wear disposable, single-use gloves for all patient contact and change them when moving from one patient to another or when they become heavily soiled. However, wearing gloves is not a substitute for proper hand washing.
Proper decontamination of the patient care compartment is essential after delivering the patient to the hospital. The respiratory syncytial virus can remain active on non-porous surfaces, skin and gloves for many hours (Hall & Douglas, 1981) . One of the most important equipment decontamination practices is to clean surfaces with soap and water before disinfection (Rutala, 1996) . Cleaning removes the foreign material from the objects while disinfection removes the microorganisms. Before disinfecting, clean with soap and water all equipment that was exposed to the patient or your gloves. This includes the stethoscope, blood pressure cuff, ECG monitor cable, stretcher, and clipboard. Once clean, wipe all surfaces in the patient care compartment with a disinfectant and allow the surfaces to air-dry. The disinfectant should be a commercial solution or a 1:10 concentration of household bleach and water (Goodman & Cone, 2001 ).
Summary
RSV is a common virus that can produce life-threatening complications in both pediatric and adult patients. RSV produces symptoms that are similar to the common cold or flu and is the most common cause of bronchiolitis in infants. Bacterial infection can complicate RSV infection resulting in pneumonia and the need for mechanical ventilation. The virus is easily transmitted from one person to another and EMS professionals must take adequate precautions to protect themselves and other patients from viral transmission.
